
Last updated: 2026-10-12 20:28:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Royalty Pharma plc (RPRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $57,80, with a market capitalisation of $25,35B and a P/E ratio of 31,10. Over the past 52 weeks, its price has ranged from $35,23 to $64,38. This page covers its latest market performance, valuation, price trends and company information.
$25,35B | |
$57,04 | |
$64,38 | |
$0,26 | |
$56,93 | |
1,89M | |
2,94M | |
31,10 | |
$64,38 | |
$35,23 | |
1,57% | |
-- |
Royalty Pharma plc (RPRX) is trading at $57,80 in after-hours trading as of 2026-10-12 20:26:00, up 1,53% ($0,87) from the regular-session close of $56,93.
After-hours trading shows how investors are pricing RPRX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Royalty Pharma plc (RPRX) moved from $57,63 to $57,80, representing a gain of 0,29% ($0,17).
The stock traded between $55,13 and $58,40 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 3,04 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 77,4%
RPRX is currently trading at $57,80, placing it 77,4% of the way from its 52-week low of $35,23 to its 52-week high of $64,38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 100 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Royalty Pharma plc (RPRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.